Skip to content
    Clinical Trials

    Phase IV Real-World Study of Acalabrutinib in Indian Patients With CLL/SLL and MCL

    Malhotra et alFrontiers in Oncology

    Phase IV Real-World Study of Acalabrutinib in Indian Patients With CLL/SLL and MCL
    In a prospective, open-label, single-arm, multicenter Phase IV study conducted across India (NCT04930536), investigators evaluated the safety, tolerability, and clinical outcomes of acalabrutinib in 89 patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL; either treatment-naive or previously treated) and 11 patients with relapsed or refractory mantle cell lymphoma (MCL). Patients received oral acalabrutinib at a dosage of 100 mg twice daily for up to six 28-day cycles or until disease progression/discontinuation, followed by a 28-day safety follow-up.
    Clinical efficacy assessments demonstrated an objective response rate (ORR) of 62% in the CLL/SLL cohort and 36% in the relapsed/refractory MCL cohort, with patients sustaining baseline quality of life measures throughout the treatment course.
    Safety monitoring identified at least one adverse event (AE) in 54% (n=48) of CLL/SLL patients and 82% (n=9) of MCL patients. Treatment-emergent adverse events (TEAEs) occurred in 43% (n=38) and 64% (n=7) of the CLL/SLL and MCL cohorts, respectively. Serious TEAEs were documented in 9% of patients with CLL/SLL and 27% of patients with MCL. Drug-related TEAEs were reported in three patients with CLL/SLL and two patients with MCL, and two drug-related deaths occurred in the MCL cohort. Discontinuations attributable to AEs were required in 3.4% of the CLL/SLL group and 18.2% of the MCL group. Investigators concluded that acalabrutinib demonstrated clinical activity and a safety profile consistent with global trial data, with no novel safety signals identified.

    Key Takeaways

    • Acalabrutinib achieved an objective response rate of 62% in the CLL/SLL cohort and 36% in the relapsed/refractory MCL cohort, with quality-of-life scores maintained across both groups.
    • Serious treatment-emergent adverse events occurred in 9% of CLL/SLL patients and 27% of MCL patients, with adverse-event-related drug discontinuation observed in 3.4% and 18.2% of patients, respectively, alongside two drug-related deaths in the MCL cohort.
    Read the original sourceFrontiers in Oncology